BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) in a best efforts public offering.

。

All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company. ThinkEquity is acting as the sole placement agent for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

公司将出售所有普通股（和/或预支认股权证）股份。ThinkEquity是本次发行的唯一配售代理。本次发行受市场条件制约，无法保证是否或何时完成本次发行，也无法保证本次发行的实际规模或条款。

The Company intends to use the net proceeds from the offering primarily for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, and related investigational new drug (IND) enabling studies, and for working capital and other general corporate purposes.

。

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-268764), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 13, 2022, and declared effective on December 16, 2022. The offering will be made only by means of a written prospectus forming part of the effective shelf registration statement.

这些证券将根据表S-3（文件号333-268764）上的货架登记声明进行发售和出售，包括2022年12月13日提交给美国证券交易委员会（“SEC”）并于2022年12月16日宣布生效的基本招股说明书。发售将仅通过书面招股说明书的形式进行，该招股说明书构成有效货架登记声明的一部分。

A preliminary prospectus supplement describing the terms of the offering, and an accompanying prospectus has been or will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained .

描述本次发行条款的初步补充招股说明书和随附招股说明书已经或将提交给美国证券交易委员会，并将在美国证券交易委员会的网站www.SEC.gov上提供。还可以获得初步补充招股说明书和随附招股说明书的副本。